Targeted Therapy

Targeted Therapy and Immunotherapy for Cancer: Treating the Tumour’s Biology, Not Just Its Address

Targeted therapy is a cancer treatment that uses medicines designed to block specific molecules — abnormal genes, proteins or signalling pathways — that cancer cells depend on in order to grow, divide and spread. It is considered when testing shows that a tumour carries a feature, called a biomarker or target, that an available drug can act on. Together with immunotherapy for cancer, it represents one of the two biggest shifts in modern oncology: treatment chosen for what the tumour is doing at a molecular level, not only for where in the body it started.

For most of medical history, cancer treatment was organised around the organ. A breast cancer was treated as a breast cancer, a lung cancer as a lung cancer, a colon cancer as a colon cancer. That framework still matters, but it is no longer the whole picture. Doctors now also study what is happening inside the cancer cells: the genetic changes, proteins and signalling pathways that help the tumour grow, spread or resist treatment. Two tumours arising in the same organ can behave completely differently. Two tumours in different organs can share the same molecular weakness. Targeted therapy exists because of that second observation.

How targeted therapy fits into a treatment plan varies from patient to patient. For some, it is used instead of traditional chemotherapy. For others, it is combined with chemotherapy, immunotherapy, hormone therapy, surgery or radiotherapy as part of a broader cancer treatment plan. There is no single sequence that applies to everyone, which is precisely why the planning stage matters as much as the drug itself.

If you are researching care abroad, targeted therapy raises practical questions. Do I need molecular testing? Is my cancer suitable for a targeted drug? What side effects should I expect? Can treatment continue after I return home? These questions deserve straight answers, because targeted therapy only works well when the drug and the tumour biology are correctly matched — and it helps to be equally clear about what the approach cannot do. At Acibadem, targeted therapy is planned through evidence-based cancer care pathways, supported by modern diagnostic testing, multidisciplinary tumour boards and experienced oncology teams, with the aim of understanding the cancer in detail before any treatment decision is made.

What Is Targeted Therapy?

Targeted therapy for cancer is a group of medicines that act on specific molecules involved in cancer growth and survival. Those molecules may be abnormal proteins, altered genes, cell-surface receptors or internal signalling pathways that cancer cells rely on. By blocking or modifying these targets, the treatment may slow cancer growth, shrink tumours, prevent cancer cells from dividing or make them more vulnerable to other treatments.

The word “targeted” is doing real work in that definition. Before a targeted drug is recommended, your oncologist usually needs evidence that the tumour actually carries the relevant biomarker. That evidence may come from tumour tissue testing, from blood-based testing known as liquid biopsy, or from both. The treatment decision is then built on cancer type, stage, previous therapies, overall health, the molecular findings and international clinical guidelines. A targeted drug given without a confirmed target is not precision medicine; it is guesswork with side effects.

How is targeted therapy different from chemotherapy?

Chemotherapy attacks rapidly dividing cells wherever it finds them; targeted therapy is designed to act on a specific molecular feature that the tumour carries. Chemotherapy can be highly effective, but because it works on fast-growing cells in general, it can also affect healthy tissue with rapid turnover — hair follicles, the lining of the digestive tract and the bone marrow. Targeted therapy is more selective. It is not free of side effects, and it is not suitable for every patient, but when a relevant target is present it offers a more individualised approach. Neither treatment replaces the other as a category: many patients receive both, in sequence or in combination, depending on the cancer and its behaviour over time.

You will sometimes see systemic cancer medicines shortened to “cancer Rx” in clinic paperwork and online resources. The shorthand flattens an important distinction: the medicines behind it — chemotherapy, targeted drugs, immunotherapies, hormonal treatments — work in fundamentally different ways, carry different side-effect profiles and suit different tumours.

What types of targeted therapy are there?

Targeted therapies fall into several categories, and the category shapes how you receive treatment. Small-molecule drugs are usually taken as tablets or capsules; they are small enough to enter cancer cells and block signals inside the cell. Monoclonal antibodies are larger molecules, usually given by intravenous infusion, that attach to targets on the surface of cancer cells or in the surrounding tumour environment. Herceptin (trastuzumab) is a well-known example: an antibody that binds the HER2 receptor found in excess on some breast and stomach cancers. Beyond these two main families, some targeted treatments block the formation of the blood vessels a tumour needs to feed itself, some interfere with the cancer cell’s DNA repair machinery, and antibody–drug conjugates use an antibody as a delivery vehicle, carrying treatment directly to cells that display a particular marker.

Immunotherapy for Cancer: How It Differs from Targeted Therapy

Immunotherapy for cancer is a treatment approach that helps your own immune system recognise and attack cancer cells, rather than attacking the cancer directly with a drug. Anyone researching targeted therapy meets it constantly, and the two are easy to confuse: both are newer than chemotherapy, both depend on the biology of the individual tumour, and some monoclonal antibodies sit in both categories at once. Setting them side by side makes the treatment landscape much easier to read.

What is immunotherapy for cancer?

Immunotherapy covers several distinct treatments. Checkpoint inhibitors release the molecular “brakes” that some cancers place on immune cells, allowing the immune system to attack the tumour. CAR-T therapy re-engineers a patient’s own T cells in the laboratory so they recognise a marker on the cancer, then returns them to the bloodstream. Other approaches include therapeutic vaccines and immune-signalling proteins. The conceptual difference from targeted therapy is direction of attack: a targeted drug acts on machinery inside or on the cancer cell itself, while immunotherapy recruits the immune system to do the attacking. Both approaches depend on testing — biomarkers such as PD-L1 expression or mismatch-repair status help predict whether immunotherapy is likely to be worthwhile, just as gene mutations guide targeted treatment.

What type of cancer can be treated with immunotherapy?

Immunotherapy has established roles in melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers, some lymphomas and tumours with specific features such as high microsatellite instability, among others. The honest caveat is that suitability is tested, not assumed. Within each of these diagnoses, some tumours have the biological features that predict a response and some do not, and there are cancers where immunotherapy currently adds little. This is why the same diagnostic discipline that governs targeted therapy — confirm the biology first, then choose the drug — applies to immunotherapy for cancer as well.

Is immunotherapy stronger than chemotherapy?

Neither is stronger in any universal sense; they work in entirely different ways, and which performs better depends on the cancer and its biomarkers. In some tumours with the right features, immunotherapy can produce responses that last far longer than chemotherapy typically achieves. In other cancers, chemotherapy remains the more dependable option, and in many situations the two are deliberately combined. “Which is stronger” is the wrong question. The useful question is: which treatment does this particular tumour’s biology predict a response to?

How long do cancer patients stay on immunotherapy?

Treatment duration varies widely and is reviewed continuously rather than fixed at the outset. Immunotherapy is usually given in cycles every few weeks. Some protocols run for a defined period; others continue for as long as the cancer is responding and side effects remain manageable; and some treatment plans set a planned stopping point, often around two years, after which the patient is monitored off treatment. The decision is individual and is revisited at each imaging assessment.

What is the life expectancy of a person on immunotherapy for cancer?

There is no honest single answer, because life expectancy depends on the cancer type, its stage, the tumour’s biomarkers, how the disease responds to treatment and the person’s general health — not on the fact of receiving immunotherapy itself. Some people with advanced disease experience unusually durable responses; others gain little benefit from the same drug. Population-level figures do not translate to individuals, which is why the meaningful conversation about prognosis happens between a patient and the oncologist who knows the specific case.

How dangerous is off-target specificity in CAR-T therapy?

It is one of the recognised serious risks of CAR-T treatment, and it is a large part of why CAR-T is delivered only in specialised units with intensive monitoring. Engineered T cells are built to attack a particular antigen; if that antigen also appears on healthy cells, the treatment can damage normal tissue — described as “on-target, off-tumour” toxicity. CAR-T also carries risks of cytokine release syndrome and neurological side effects. These risks are managed through strict patient selection, inpatient observation and established treatment protocols for complications. They are serious, but they are anticipated and planned for rather than hidden — which is the standard any patient should expect from a centre offering cellular therapy.

Who May Need Targeted Therapy?

Targeted therapy may be considered for any patient whose cancer carries a molecular feature that an available targeted drug can act on. It is used across many cancer types, including certain forms of lung cancer, breast cancer, colorectal cancer, melanoma, kidney cancer, liver cancer, gastrointestinal stromal tumours, ovarian cancer, thyroid cancer, some leukaemias and lymphomas, and other solid and blood cancers. Suitability depends less on the general cancer name and more on the tumour’s biological profile — the recurring theme of this entire field.

Patients arrive at this point along different routes. Some first come to medical attention because of symptoms: a persistent cough, unexplained weight loss, fatigue, pain, changes in bowel habits, abnormal bleeding, a lump, skin changes, swollen lymph nodes or symptoms related to a specific organ. Others have their cancer detected through screening, routine imaging or follow-up after previous treatment.

The diagnostic pathway usually begins with clinical examination, imaging and tissue confirmation. A biopsy or surgical specimen allows pathologists to identify the cancer type and grade. Imaging — computed tomography, magnetic resonance imaging, ultrasound, mammography, positron emission tomography or other specialised scans — establishes the extent of disease. Laboratory tests assess organ function and readiness for treatment.

For targeted therapy specifically, the critical next step is biomarker testing. Depending on the cancer type, this may include immunohistochemistry, fluorescence or chromogenic in situ hybridisation, polymerase chain reaction testing, next-generation sequencing or other molecular methods. These tests look for gene mutations, gene fusions, amplifications, protein expression levels or other markers that determine whether a targeted drug is a genuine option.

When is targeted therapy recommended?

Targeted therapy is recommended when biomarker testing confirms an actionable target and the clinical situation supports its use — which can arise at several points in a cancer journey. It may be recommended after surgery, to reduce the risk of recurrence in selected cancers. It may be used before surgery, to shrink a tumour and improve the chance of local control. It is frequently used when cancer has spread, when it returns after earlier treatment, or when standard therapies are less likely to work. Sometimes it is the clear first choice because the tumour carries a highly actionable biomarker; sometimes it enters the picture only after previous treatments and molecular results have been reviewed together.

Equally important: not every patient with cancer needs targeted therapy. Some cancers have no currently treatable target, and some patients are better served by surgery, radiotherapy, immunotherapy, chemotherapy, active surveillance or supportive care. A careful specialist review protects against both under-treatment and unnecessary treatment.

Which Cancers Can Targeted Therapy Address?

Targeted therapy is used across a broad range of diagnoses, but the indication is always specific. A drug that works for one mutation in one cancer type may do nothing for a different mutation, or for the same mutation in a different tumour environment. This is why treatment planning demands both oncology expertise and reliable pathology and molecular testing — the drug list means little without the biology behind it.

What is targeted therapy for lung cancer?

Targeted therapy for lung cancer means matching a drug to a specific driver alteration found in the tumour — changes in genes such as EGFR or rearrangements involving ALK are well-known examples. These alterations act like a stuck “on switch” for cancer growth, and targeted drugs are designed to block that signal. In practice, this makes molecular testing a standard early step in modern lung cancer care: the result determines whether a patient’s first treatment is a targeted tablet, chemotherapy, immunotherapy or a combination.

In breast cancer, targeted treatments are used for tumours that express particular receptors or gene amplifications — HER2-directed antibodies being the best-known example — often alongside hormone therapy, chemotherapy or other systemic treatments. In colorectal cancer, molecular testing does double duty: it identifies which targeted approaches may help and, just as importantly, which would not be effective for that particular tumour.

In melanoma, targeted medicines are an option when specific mutations are present, sometimes given alongside or in sequence with immunotherapy. In kidney cancer and liver cancer, certain targeted therapies act on blood-vessel growth signals and other pathways that support tumour progression. In ovarian, prostate, pancreatic and some other cancers, drugs that interfere with DNA repair mechanisms may be considered when particular inherited or tumour-related changes are found — one of the situations where a tumour finding can also carry implications for a patient’s family.

Blood cancers have important targeted options of their own. Certain leukaemias and lymphomas are driven by defined molecular abnormalities or cell-surface markers that can be treated with oral targeted medicines, antibody-based therapies or other specialised agents. In some of these diseases, targeted therapy is not an add-on but the backbone of long-term disease control for selected patients.

Finally, targeted therapy may be considered for rare cancers when comprehensive molecular profiling identifies an actionable alteration. In some cases a tumour-agnostic indication applies: the treatment is chosen because of a biomarker, regardless of the organ where the cancer began. These decisions require careful weighing of the strength of the evidence, approved indications, the patient’s condition and the available alternatives — the newer the indication, the more this scrutiny matters.

How Targeted Therapy Is Planned and Delivered

Targeted therapy begins long before the first dose. A typical pathway moves through six stages:

1. Case review. The oncology team reviews medical history, pathology reports, imaging, previous treatments, current medications and overall health. Existing biopsy samples may be re-examined by pathology specialists to confirm the diagnosis and judge whether further testing is needed.
2. Biomarker evaluation. Testing is performed on tumour tissue from a biopsy or surgery. Where tissue is limited or a new biopsy is impractical, a blood-based liquid biopsy may look for circulating tumour DNA — useful in advanced disease, though it does not replace tissue testing in every situation.
3. Multidisciplinary discussion. The case is discussed in a tumour board bringing together medical oncologists, radiation oncologists, surgeons, radiologists, pathologists, nuclear medicine physicians and genetic counsellors as needed, so the treatment strategy reflects several specialist perspectives and international evidence-based protocols.
4. Defining the goal. The team explains what the treatment is for: reducing recurrence risk after local treatment, shrinking a tumour before surgery, controlling metastatic disease, relieving symptoms or delaying progression. Alternatives, monitoring plans and likely side effects are covered at the same stage.
5. Treatment delivery. Oral targeted drugs are taken at home on a defined schedule, with instructions covering timing, food interactions, missed doses, storage and interactions. Infusion-based treatments are given in an oncology day unit, with pre-treatment assessment, blood tests, vital-sign checks and monitoring during and after the infusion; early doses of some antibody treatments require observation for infusion reactions.
6. Monitoring and reassessment. Scheduled blood tests and imaging track both tolerability and response, and the plan is adjusted whenever the evidence changes.

The technology involved extends well beyond the medication itself. Modern targeted treatment relies on advanced imaging to stage disease and monitor response, digital pathology and molecular diagnostics to identify biomarkers, laboratory systems to track organ function, and electronic treatment-planning tools to support safe dosing. In selected cases, image-guided biopsy techniques allow tissue to be obtained from difficult-to-reach lesions with greater precision. All of it serves the same purpose: matching treatment to the patient and adjusting the match as the disease evolves.

Treatment duration varies widely. Some targeted therapies are given for a defined period after surgery. Others continue for as long as the cancer is responding and side effects remain manageable. In advanced cancer, targeted therapy is often part of ongoing disease control, with regular imaging and blood tests evaluating response. If the cancer develops resistance — a real possibility with any targeted drug — additional molecular testing may be recommended to look for new changes that could open a different treatment route.

Side effects depend on the specific drug and its target. They may include skin rash, diarrhoea, fatigue, mouth sores, changes in liver tests, high blood pressure, bleeding risk, changes in heart function, lung inflammation, thyroid changes, eye symptoms, blood-count changes or hand-foot skin reactions. Many are manageable when recognised early, which is why patients are taught which symptoms need urgent reporting to their care team and which can wait for a routine visit.

It also helps to reset expectations about “recovery”. Targeted therapy has no single recovery period in the way surgery does; instead there is a period of adjustment as the body adapts to treatment. Some people continue most daily activities, keep working and travel with planning. Others need dose adjustments, temporary treatment breaks or supportive medications, all decided by the treating oncologist. A good oncology team monitors quality of life alongside cancer response, because a plan that cannot be tolerated is not an effective plan.

Why Acting Early Matters

In cancer care, timing shapes options. Acting early does not mean starting treatment the same day; it means avoiding unnecessary delay in diagnosis, staging, biomarker testing and specialist review. For patients who may benefit from targeted therapy, the molecular results are the hinge of the whole plan — if testing is delayed, the most appropriate treatment is delayed with it.

Some cancers grow or spread quickly. Prolonged delay can allow symptoms to worsen, organ function to decline or general fitness to deteriorate, and a patient who is strong enough for several treatment options at diagnosis may have fewer options after significant progression. Early evaluation also surfaces urgent problems — spinal cord compression, airway compromise, liver obstruction, blood clots, brain metastases — that need attention in their own right.

Timely biomarker testing carries particular weight in cancers where targeted therapy is a preferred first treatment for specific molecular subtypes. Starting a less suitable therapy before molecular results are known can complicate treatment sequencing and expose a patient to side effects without the best chance of benefit. Sometimes, of course, treatment must begin before all results are back because the cancer is causing urgent symptoms — a judgement that calls for experienced clinical hands.

There is an emotional dimension too. Uncertainty is one of the hardest parts of a cancer diagnosis, and a structured plan — even one that includes further testing before treatment — gives patients and families a clear picture of what is happening and why. For international patients, early coordination also leaves time to gather records, arrange travel, understand the expected treatment duration and plan follow-up after returning home.

Potential Benefits of Targeted Therapy

What targeted therapy offers depends on the cancer type, the biomarker, the disease stage and the individual patient — but when the drug and the tumour biology are well matched, several advantages become relevant.

Benefit	What It Means for You
More individualised treatment	Treatment is selected on the molecular features of your cancer, not only its location in the body.
Potential for meaningful tumour control	When the cancer depends on a target the drug can block, targeted therapy may slow growth or reduce tumour size.
Often less broadly toxic than traditional chemotherapy	Because treatment is directed at specific pathways, some patients experience fewer classic chemotherapy effects — though side effects still occur and need managing.
Convenient options for some patients	Many targeted therapies are taken by mouth, which may reduce hospital time where this is appropriate and safe.
Useful in combination strategies	Targeted therapy may be combined with surgery, radiotherapy, immunotherapy, chemotherapy or hormone therapy to improve disease control in selected cases.
Ongoing monitoring and adjustment	Your care team assesses response and side effects over time, adjusting the dose or treatment sequence when the evidence calls for it.

Recovery and Treatment Timeline

Timelines vary by drug and cancer type, but the overview below reflects what many patients can expect around treatment initiation and follow-up.

Time Period	What Patients Can Expect
Day 1	You start an oral medication at home with detailed instructions, or receive an infusion in the oncology unit. Baseline symptoms, vital signs and laboratory results are reviewed.
First week	The care team watches for early side effects such as rash, diarrhoea, fatigue, blood-pressure changes or infusion-related symptoms, depending on the drug.
First month	Blood tests and clinical visits assess tolerability. Dose adjustments or supportive medications are introduced if side effects appear.
First imaging check	Scans are scheduled after an appropriate treatment interval to evaluate whether the cancer is responding, stable or progressing.
Longer term	Treatment continues while it remains effective and manageable. Ongoing monitoring looks for resistance, late side effects and changes in overall health.

What Influences the Success of Targeted Therapy?

A good result depends on several connected factors, and it is worth understanding each of them before treatment begins.

Accuracy of diagnosis. The cancer type, stage and molecular profile must be correctly identified. High-quality pathology review and appropriate biomarker testing are non-negotiable, because the wrong target, incomplete testing or insufficient tissue leads directly to an ineffective treatment choice.

Strength of the target. Some molecular changes are true drivers of cancer growth — the tumour depends heavily on that pathway, and an effective drug against a strong driver alteration has a better chance of helping. Other findings are less clearly actionable, particularly where the evidence base is thin or the alteration is only one strand of a complex tumour biology. An honest oncologist will distinguish between the two rather than treating every finding as an opportunity.

Stage and disease burden. Targeted therapy behaves differently in early-stage disease, locally advanced cancer and metastatic cancer. The location of metastases, brain involvement, liver and kidney function, blood counts and overall physical condition all influence both what can be offered and how well it is tolerated.

Previous treatments and resistance. A cancer that has been through several lines of therapy may have developed resistance mechanisms. Sometimes a new biopsy or liquid biopsy can identify why resistance occurred and whether another targeted option is reasonable; sometimes switching to a different treatment class is the better move.

Adherence and interactions. For oral targeted drugs, taking the medication at the correct dose and schedule genuinely affects disease control. Oncology teams ask for a complete list of prescriptions, supplements, herbal products and over-the-counter medicines because interactions can change drug levels or amplify side effects. Any decision to adjust, pause or change a dose belongs to the treating oncologist — side effects reported early are far easier to manage than side effects endured in silence.

Side-effect management. Skin-care plans, anti-diarrhoeal treatment, blood-pressure control, liver monitoring, cardiac assessment, thyroid checks or temporary dose changes can all help patients stay on effective treatment safely. The aim is never only tumour control; it is preserving strength, nutrition, mobility and daily function alongside it.

Coordinated reassessment. Cancer care changes over time. A treatment that is right today may need adjusting if scans change, new symptoms develop or new molecular information appears. Regular structured review keeps the plan aligned with both the medical picture and the patient’s own goals.

How Acibadem Approaches Targeted Therapy

Patients considering targeted therapy usually need more than a prescription: a reliable diagnosis, a clear explanation of the options, coordinated testing, safe treatment delivery and a plan that survives the journey home. Acibadem’s cancer care is structured around those needs, with care planning guided by physicians across medical oncology, surgical oncology, radiation oncology, radiology, pathology, nuclear medicine and related specialties. Where appropriate, cases are reviewed in multidisciplinary tumour boards that weigh the diagnosis, stage, molecular findings and treatment sequence together — particularly valuable in targeted therapy, where the best plan often involves more than one treatment method and depends on timing.

Diagnostic pathways support the personalisation. Molecular testing, pathology review, imaging and laboratory evaluation establish whether a target is present and whether the patient is ready for treatment. Where findings suggest a hereditary cancer syndrome, genetic counselling may be recommended, since such results can affect family members and future screening.

Acibadem International provides dedicated services for patients travelling from abroad, including assistance with medical record review, appointment coordination and translation support — practical help that matters most to patients comparing treatment recommendations across countries, where clear communication about the purpose, duration and requirements of targeted therapy prevents expensive confusion.

Continuity is treated as part of the treatment itself. Targeted therapy may continue for months or longer, with periodic imaging and blood tests, so care plans set out what needs monitoring locally after travel, what information should reach home physicians, and when return visits make sense. And because complex cancer decisions require honesty as much as expertise, the limitations are explained alongside the potential: targeted therapy can be genuinely valuable for the right patient, but resistance can develop, side effects can require changes of course, and it is not a universal answer. Patients decide better on evidence than on hope alone.

Weighing Targeted Therapy as an Option

Targeted therapy represents a more precise way of treating many cancers, but its value rests entirely on matching the right medicine to the right tumour biology at the right time. For anyone weighing a diagnosis, conflicting recommendations or the question of whether molecular testing could change the plan, the essentials are consistent: a confirmed pathology diagnosis, complete biomarker testing appropriate to the cancer type, and a multidisciplinary review that considers targeted therapy alongside surgery, radiotherapy, chemotherapy, immunotherapy and hormonal treatment rather than in isolation. Complete medical records, imaging files and pathology reports are what make any such assessment accurate — the more of the tumour’s story a team can see, the more precisely treatment can be matched to it.